These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 10699372)

  • 1. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients.
    Lopiano L; Chiesa M; Digilio G; Giraudo S; Bergamasco B; Torre E; Fasano M
    Biochim Biophys Acta; 2000 Mar; 1500(3):306-12. PubMed ID: 10699372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPR investigations of the iron domain in neuromelanin.
    Aime S; Bergamasco B; Biglino D; Digilio G; Fasano M; Giamello E; Lopiano L
    Biochim Biophys Acta; 1997 Jul; 1361(1):49-58. PubMed ID: 9247089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease.
    Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ
    Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies.
    Fasano M; Bergamasco B; Lopiano L
    J Neural Transm (Vienna); 2006 Jun; 113(6):769-74. PubMed ID: 16755381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano-secondary ion mass spectrometry.
    Biesemeier A; Eibl O; Eswara S; Audinot JN; Wirtz T; Pezzoli G; Zucca FA; Zecca L; Schraermeyer U
    J Neurochem; 2016 Jul; 138(2):339-53. PubMed ID: 27121280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a glycidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra.
    Aime S; Fasano M; Bergamasco B; Lopiano L; Valente G
    J Neurochem; 1994 Jan; 62(1):369-71. PubMed ID: 8263538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
    Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
    J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study.
    Shima T; Sarna T; Swartz HM; Stroppolo A; Gerbasi R; Zecca L
    Free Radic Biol Med; 1997; 23(1):110-9. PubMed ID: 9165303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XANES spectroscopy of a single neuron from a patient with Parkinson's disease.
    Yoshida S; Ektessabi A; Fujisawa S
    J Synchrotron Radiat; 2001 Mar; 8(Pt 2):998-1000. PubMed ID: 11513007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
    Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
    Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.
    Zecca L; Berg D; Arzberger T; Ruprecht P; Rausch WD; Musicco M; Tampellini D; Riederer P; Gerlach M; Becker G
    Mov Disord; 2005 Oct; 20(10):1278-85. PubMed ID: 15986424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
    Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
    J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mössbauer spectroscopy and ELISA studies reveal differences between Parkinson's disease and control substantia nigra.
    Galazka-Friedman J; Bauminger ER; Koziorowski D; Friedman A
    Biochim Biophys Acta; 2004 Mar; 1688(2):130-6. PubMed ID: 14990343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes.
    Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L
    Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain.
    Zecca L; Shima T; Stroppolo A; Goj C; Battiston GA; Gerbasi R; Sarna T; Swartz HM
    Neuroscience; 1996 Jul; 73(2):407-15. PubMed ID: 8783258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total and paramagnetic metals in human substantia nigra and its neuromelanin.
    Zecca L; Swartz HM
    J Neural Transm Park Dis Dement Sect; 1993; 5(3):203-13. PubMed ID: 8396395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease and iron.
    Mochizuki H; Choong CJ; Baba K
    J Neural Transm (Vienna); 2020 Feb; 127(2):181-187. PubMed ID: 32025811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra.
    Gerlach M; Trautwein AX; Zecca L; Youdim MB; Riederer P
    J Neurochem; 1995 Aug; 65(2):923-6. PubMed ID: 7616255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta.
    Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP
    Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.